Low luteal progesterone increases prostaglandin activity and uterine contractility, causing painful periods.

The physiological relationship between luteal progesterone, prostaglandin synthesis, and uterine contractility is a well-established pathway in the pathogenesis of primary dysmenorrhea (painful periods). Research confirms that progesterone levels during the luteal phase act as a critical regulatory brake on the inflammatory processes that drive menstrual pain.

Clinical and Mechanistic Evidence

The link between low progesterone and increased prostaglandin activity is supported by robust mechanistic data:

• Progesterone as a Suppressor: During a healthy luteal phase, progesterone maintains endometrial quiescence by inhibiting the expression of cyclooxygenase-2 (COX-2), the rate-limiting enzyme for prostaglandin production. It effectively suppresses the NF-kappaB signaling pathway, which is the primary driver of endometrial inflammation.
• Prostaglandin Surge: When progesterone levels are low—either due to natural luteal regression or luteal phase deficiency—this inhibition is removed. The resulting activation of NF-kappaB leads to a significant surge in Prostaglandin F2α (PGF2α) and Prostaglandin E2 (PGE2).
• Uterine Hypercontractility: Elevated PGF2α binds to specific receptors on the myometrium (uterine muscle), triggering an influx of intracellular calcium. This causes high-amplitude, frequent, and dysrhythmic uterine contractions. In women with dysmenorrhea, intrauterine pressures can exceed 120 mmHg, significantly higher than the pressures seen in pain-free cycles.

Pathophysiological Link to Pain

The pain associated with these contractions is primarily ischemic in nature:

• Vasoconstriction and Ischemia: Excessive uterine contractions compress the small blood vessels supplying the myometrium. This leads to reduced blood flow (ischemia) and subsequent tissue hypoxia.
• Sensitization of Nociceptors: The ischemic environment, combined with the direct action of prostaglandins, sensitizes uterine pain fibers (nociceptors). This process creates the characteristic cramping and systemic symptoms often associated with dysmenorrhea.
• Pharmacological Validation: The effectiveness of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in treating period pain further validates this mechanism; by inhibiting COX enzymes and reducing prostaglandin levels, these drugs directly decrease uterine contractility and alleviate pain.

Bottom line

Lower luteal progesterone levels lead to increased prostaglandin synthesis (specifically PGF2α), which triggers uterine hypercontractility and subsequent muscle ischemia. This sequence is a primary biological cause of painful periods.